Pharming Group PHAR 深 沪
等待开盘 10-30 09:30:00 美东时间
12.13
-0.130
-1.06%
华盛通- 最 高12.27
- 今 开12.25
- 成交量 1.24万股
- 最 低 11.75
- 昨 收 12.26
- 总市值 8.59亿
- 52周最高 21.34
- 市盈率 静 316.71
- 换手率 0.02%
- 52周最低 9.11
- 委 比 39.39%
- 总股本 7077.81万
- 历史最高 21.99
- 量 比 0.45
- 振 幅 4.24%
- 历史最低 6.10
- 每 手 1
- 风险率 2.78%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Pharming Q3 EPS $0.30 Beats $0.02 Estimate, Sales $117.600M Miss $117.733M Estimate
Pharming (NASDAQ:PHAR) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.02 by 1400 percent. This is a 200 percent increase over earnings of $0.10 per share from the same period last year. The company reported quarterly sales of $117.600 million which mis...
10-27 14:13
Pharming Group收涨6.25%，成交额51.06万美元
10月27日，Pharming Group（PHAR）收涨6.25%，报11.9美元，成交额51.06万美元，市值8.42亿美元。 行情数据 • 开盘价：11...
10-27 05:50
Healthcare Services Posts Upbeat Q3 Earnings, Joins Pool, Spotify And Other Big Stocks Moving Higher On Thursday
U.S. stocks were lower, with the Nasdaq Composite falling around 500 points on Thursday. Shares of Healthcare Services Group Inc (NASDAQ:HCSG) rose sharply following strong quarterly earnings. Healthcare Services reported quarterly earnings of 36 cents per share which beat the analyst consensus esti...
10-22 22:29
Pharming Narrows FY2026 Sales Guidance from $375.000M-$395.000M to $380.000M-$390.000M vs $389.333M Est
Pharming (NASDAQ:PHAR) narrows FY2026 sales outlook from $375.000 million-$395.000 million to $380.000 million-$390.000 million vs $389.333 million estimate.
10-22 13:29
Pharming Group announces third quarter 2026 revenues above market expectations
Pharming Group N.V. reported a 21% increase in Q3 2026 revenues to $117.6 million, driven by strong performance of RUCONEST® and Joenja®. Operating expenses remained stable at $74.6 million. The company tightened its 2026 revenue guidance to $380-$390 million and lowered operating expense guidance to $310-$315 million. Clinical updates include positive Phase II data for leniolisib and progress in the FALCON trial for Napazimone. Full Q3 results a...
10-22 05:00
Pharming Group收跌2.8%，成交额8.5万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 06:00
Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026
Pharming presented positive Phase II data for leniolisib in primary immunodeficiencies (PIDs) with immune dysregulation linked to altered PI3Kδ signaling. The study showed leniolisib was well-tolerated, with improvements in spleen volume, lymph nodes, pulmonary function, and liver disease. All 12 participants who completed the trial enrolled in a long-term extension study. These findings support the potential of leniolisib to address immune dysre...
10-14 06:00
Pharming CEO Fabrice Chouraqui steps down
Pharming (PHAR) said Fabrice Chouraqui will step down as CEO and executive director with immediate effect following a mutual agreement with the company’s board. “Following discussions about the execut...
09-29 17:39
Pharming announces CEO transition
Pharming Group announced that CEO Fabrice Chouraqui has stepped down, with the Board appointing Leverne Marsh and Kenneth Lynard as interim co-CEOs. The decision followed a strategic alignment discussion. The company's strategy and commitment to patients remain unchanged, with a focus on advancing growth and executing priorities. The Board has initiated a search for a permanent successor.
09-29 05:00
Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026
Pharming announced positive topline results from its Phase II trial of leniolisib in primary immunodeficiencies (PIDs) with immune dysregulation linked to PI3Kd signaling. The study demonstrated favorable safety, tolerability, and clinical improvements, including a 26.4% mean spleen volume reduction. Leniolisib is the first targeted treatment for APDS and is under evaluation for broader PID applications. Pharming expects to report Phase II result...
09-22 05:00
